Pulse Biosciences Bolsters Executive Team with New COO and CMO Appointments

Pulse Biosciences, Inc. (PLSE) announced a strategic restructuring of its executive leadership team on Thursday, bringing in seasoned industry expertise to drive its bioelectric medicine initiatives. The company has appointed Liane Teplitsky as Chief Operating Officer, while simultaneously expanding the responsibilities of David Kenigsberg, who will now serve as the full-time Chief Medical Officer. Teplitsky enters the role with two decades of experience in leading and scaling innovative medical technology businesses. Her professional background includes a tenure as the Chief Executive of Artedrone, as well as senior commercial and marketing leadership positions at industry giants Abbott Laboratories and St. Jude Medical. These appointments signal a focus on commercial scaling and enhanced medical oversight as the company advances its specialized medicine portfolio. The addition of Teplitsky's operational experience is expected to support the company's growth trajectory in the competitive med-tech landscape. In pre-market trading following the announcement, PLSE shares were priced at $19, reflecting a slight decline of 0.31% on the Nasdaq. The market reaction remains muted as investors assess the long-term impact of the leadership changes.